1DiMasi JA.Risks in new drug development:approval success rates for investigational drugs[J].Clin Pharmacol Ther,2001,69:297-307.
2Giaccotto C,Santerre RE,Vernon JA.Drug prices and research and development investment behavior in the pharmaceutical industry[J].JLaw Econ,2005,48:195-214.
8Green C.Considering the value associated with innovation in health technology appraisal decisions (deliberations):a NICE thing to do?[J].Appl Health Econ Health Policy,2010,8:1-5.
9Tang SL,Tao JJ,Bekedam H.Controlling cost escalation of healthcare:making universal health coverage sustainable in China[EB/OL].[2014-02-28].http://www.ncbi.nlm.nih.gov/pubmed/22992484/.
4Pelc Alain & Castan JP(1994): New Developments in Pricing and Drug Reimbursement in France.Pharmacoeconomics. 6(Suppl. 1) :28- 35.
5Towse A (1994):The Pricing and Reimbursement of Pharmaceuticals. Pharmacoeconomics. 6( Suppl.1) : 36- 38.
6Annemans L.et al (1997): Pricing and Reimbursement of pharmaceuticals in Belgium. Pharmacoeconomics.11(3):203 - 209.
7Jonsson B(1994):Pricing and Reimbursement of Pharmaceuticals in Sweden.Pharmacoeconomics. 6(Suppl. 1) :51 - 60.
8Rigtre H (1994): Recent Public Policies in the Netherlands to control Pharmaceutical Pricing and Reimbursement. Pharmacoeconomics. 6(Suppl. 1) : 15- 21.
9Thomas Ⅲ LG(1994) : Pricing, Regulation, and Competitiveness: Lessons for he US form the Japanese Pharmaceutical industry. Pharmacoeconomics. 6(Suppl. 1) : 67-70.
10Dickson M & Redwood H(1998) : Pharmaceutical Reference Prices: How Do They Work in Practice. Pharmacoeconomics. 14(5) :471 - 479.
10Acosta A, Ciapponi A, Aaserud M, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies [J].Cochrane Database Syst Rev,2014,10( 12):D5979.
